In this study the raising and development of the antibody response to Borrelia burgdorferi infection in 66 Italian patients suffering from culture-confirmed Lyme borreliosis erythema migrans (EM) was investigated. 62/66 cultures obtained from the biopsies were identified as B. afzelii by PCR A total of 175 serially collected serum samples were tested by using two different sets of commercial assays: Enzygnost® Lyme link VlsE/IgG and Enzygnost® Borreliosis IgM (DADE Behring, Marburg, Germany) and LIAISON® Borrelia IgG and IgM (Saluggia Italy). Considering only samples obtained at first presentation when EM was clinically evident, 49/66 patients (72.4%) were IgG or IgM positive by Enzygnost®, whereas 33/66 (50.0%) patients were IgG or IgM positive by LIAISON®. Taking into account the follow up period, 8 patients sero-converted for IgG or IgM by Enzygnost® and 4 by LIAISON®. Similar and very good specificity values were obtained by all the methods, by testing sera obtained from blood donors (n=300) and from patients suffering from some of the most common biological conditions possibly resulting in false-positive reactivity in Lyme disease serology (n=100): Enzygnost® Lyme link VlsE/IgG was the more specific (98.3%), followed by LIAISON® Borrelia IgG (96.5%); considering IgM tests, Enzygnost® Borreliosis IgM showed to be 95.3%% specific, whereas the LIAISON® Borrelia IgM was 92.8% specific. Recombinant VlsE antigens obtained from all the three B.burgdorferi genospecies pathogenic to humans, included in Enzygnost® Lyme link VlsE/IgG, greatly improved serodiagnosis of Lyme disease.

Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis.

MARANGONI, ANTONELLA;ACCARDO, SILVIA;CEVENINI, ROBERTO
2008

Abstract

In this study the raising and development of the antibody response to Borrelia burgdorferi infection in 66 Italian patients suffering from culture-confirmed Lyme borreliosis erythema migrans (EM) was investigated. 62/66 cultures obtained from the biopsies were identified as B. afzelii by PCR A total of 175 serially collected serum samples were tested by using two different sets of commercial assays: Enzygnost® Lyme link VlsE/IgG and Enzygnost® Borreliosis IgM (DADE Behring, Marburg, Germany) and LIAISON® Borrelia IgG and IgM (Saluggia Italy). Considering only samples obtained at first presentation when EM was clinically evident, 49/66 patients (72.4%) were IgG or IgM positive by Enzygnost®, whereas 33/66 (50.0%) patients were IgG or IgM positive by LIAISON®. Taking into account the follow up period, 8 patients sero-converted for IgG or IgM by Enzygnost® and 4 by LIAISON®. Similar and very good specificity values were obtained by all the methods, by testing sera obtained from blood donors (n=300) and from patients suffering from some of the most common biological conditions possibly resulting in false-positive reactivity in Lyme disease serology (n=100): Enzygnost® Lyme link VlsE/IgG was the more specific (98.3%), followed by LIAISON® Borrelia IgG (96.5%); considering IgM tests, Enzygnost® Borreliosis IgM showed to be 95.3%% specific, whereas the LIAISON® Borrelia IgM was 92.8% specific. Recombinant VlsE antigens obtained from all the three B.burgdorferi genospecies pathogenic to humans, included in Enzygnost® Lyme link VlsE/IgG, greatly improved serodiagnosis of Lyme disease.
Marangoni A.; Moroni A.; Accardo S.; and Cevenini R.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/96019
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 28
social impact